XML 44 R23.htm IDEA: XBRL DOCUMENT v3.25.3
Business Segment Information
 12 Months Ended
Oct. 31, 2025
Segment Reporting [Abstract]  
Business Segment Information
Note 12. Business Segment Information
The Company discloses information about its operating segments, which were established based on the way that our Chief Operating Decision Maker (CODM) organizes segments within the Company for making operating decisions and assessing financial performance. Our CODM is our Chief Executive Officer. The Company's two operating segments are described below.
•CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics.
•CooperSurgical. Competes in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception.
The CODM uses operating income, as presented in our financial reports, as the primary measure of segment profitability to assess the performance of the segments and make decisions on resource allocation across segments. The Company does not allocate costs from corporate functions to segment operating income. The Company uses the same accounting policies to generate segment results as it does for consolidated results.
No customers accounted for 10% or more of our consolidated net revenue in fiscal 2025, 2024 and 2023.
Total identifiable assets are those used in continuing operations except cash and cash equivalents, which the Company includes as corporate assets.
The following table presents a summary of our business segment net sales:
(In millions)202520242023
CooperVision net sales by category:
Toric and multifocal$1,351.3 $1,257.2 $1,134.4 
Sphere, other1,392.5 1,352.2 1,289.3 
Total CooperVision net sales2,743.8 2,609.4 2,423.7 
CooperSurgical net sales by category:
Office and surgical 824.0 774.7 689.5 
             Fertility524.6 511.3 480.0 
Total CooperSurgical net sales1,348.6 1,286.0 1,169.5 
Total net sales$4,092.4 $3,895.4 $3,593.2 
Information by business segment for each of the years in the three-year period ended October 31, 2025, follows:
(In millions)CooperVisionCooperSurgical
Corporate (1)
Consolidated
2025
Net sales$2,743.8 $1,348.6 $— $4,092.4 
Cost of sales
932.6 477.7 — 1,410.3 
Amortization expense
21.0 178.2 — 199.2 
Selling, general and administrative expense969.3 568.4 90.1 1,627.8 
Research and development expense
91.3 80.9 — 172.2 
Operating income (loss)$729.6 $43.4 $(90.1)$682.9 
Interest expense100.0 
Other expense, net16.4 
Income before income taxes$566.5 
Identifiable assets$7,604.4 $4,619.3 $171.1 $12,394.8 
Depreciation expense$153.2 $25.0 $— $178.2 
Capital expenditures$322.9 $39.5 $— $362.4 
2024
Net sales$2,609.4 $1,286.0 $— $3,895.4 
Cost of sales
911.4 388.3 — 1,299.7 
Amortization expense
28.2 173.0 — 201.2 
Selling, general and administrative expense910.7 534.2 88.8 1,533.7 
Research and development expense
82.9 72.2 — 155.1 
Operating income (loss)$676.2 $118.3 $(88.8)$705.7 
Interest expense114.3 
Other expense, net9.1 
Income before income taxes$582.3 
Identifiable assets$7,285.1 $4,832.0 $198.1 $12,315.2 
Depreciation expense$151.8 $22.1 $— $173.9 
Capital expenditures$388.6 $32.6 $— $421.2 
2023
Net sales$2,423.7 $1,169.5 $— $3,593.2 
Cost of sales
858.6 376.7 — 1,235.3 
Amortization expense
32.9 153.3 — 186.2 
Selling, general and administrative expense871.1 559.4 70.7 1,501.2 
Research and development expense
73.4 64.0 — 137.4 
Operating income (loss)$587.7 $16.1 $(70.7)$533.1 
Interest expense105.3 
Other expense, net14.9 
Income before income taxes$412.9 
Identifiable assets$7,044.0 $4,351.8 $263.1 $11,658.9 
Depreciation expense$156.9 $24.6 $— $181.5 
Capital expenditures$364.4 $28.1 $— $392.5 
(1) Corporate SGA expenses are not allocated to the segments.
Information by geographical area by country of domicile for each of the years in the three-year period ended October 31, 2025, follows:
(In millions)United
States		EuropeRest of
World, Other
Eliminations
& Corporate		Consolidated
2025
Net sales to unaffiliated customers$2,054.0 $1,253.2 $785.2 $4,092.4 
Sales between geographic areas679.0 1,124.8 (1,803.8)— 
Net sales$2,733.0 $2,378.0 $(1,018.6)$4,092.4 
Operating income$4.2 $662.1 $16.6 $682.9 
Long-lived assets$1,389.4 $429.1 $263.5 $2,082.0 
2024
Net sales to unaffiliated customers$1,965.9 $1,155.9 $773.6 $3,895.4 
Sales between geographic areas602.9 1,065.2 (1,668.1)— 
Net sales$2,568.8 $2,221.1 $(894.5)$3,895.4 
Operating income$74.2 $601.8 $29.7 $705.7 
Long-lived assets$1,188.8 $401.7 $272.9 $1,863.4 
2023
Net sales to unaffiliated customers$1,812.2 $1,041.2 $739.8 $3,593.2 
Sales between geographic areas563.1 1,016.7 (1,579.8)— 
Net sales$2,375.3 $2,057.9 $(840.0)$3,593.2 
Operating (loss) income$— $516.2 $16.9 $533.1 
Long-lived assets$1,027.6 $325.9 $279.1 $1,632.6